Sage therapeutics, inc. (SAGE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities
Net loss

-680,238

-372,882

-270,120

-158,987

-94,495

-33,811

-18,281

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

153,231

101,963

35,534

23,020

15,240

2,512

61

Non-cash licensing and consulting fees

-

-

-

-

1,211

127

64

Premium on marketable securities

3,674

215

105

756

-

-

-

Amortization of discount on marketable securities

6,966

9,892

293

-286

-

-

-

Depreciation

2,300

1,100

500

281

115

51

47

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

4,781

15,462

1,127

3,362

681

715

317

Other long-term assets

3,793

-

-

-

-

-

-

Right-of-use operating asset

-8,168

-

-

-

-

-

-

Operating lease liabilities, current

2,804

-

-

-

-

-

-

Operating lease liabilities, non-current

-10,761

-

-

-

-

-

-

Accounts payable

-18,783

24,544

-3,693

7,796

2,590

441

674

Accrued expenses and other liabilities

33,804

10,130

19,996

13,044

5,339

4,353

236

Net cash used in operating activities

-528,706

-260,671

-219,277

-118,678

-70,681

-27,042

-17,516

Proceeds from sales and maturities of marketable securities

1,171,270

974,757

261,225

30,499

-

-

-

Purchases of marketable securities

1,308,675

1,484,358

244,403

259,093

-

-

-

Purchases of property and equipment

5,751

2,860

1,360

1,421

198

128

3

Net cash provided by (used in) investing activities

-143,156

-512,461

15,462

-230,015

-198

-128

-3

Cash flows from financing activities
Proceeds from stock option exercises and employee stock purchase plan issuances

48,850

29,108

15,972

1,406

730

40

51

Payment of employee tax obligations related to vesting of restricted stock units

2,175

904

-

-

-

-

-

Payments of offering costs

328

340

179

599

584

2,285

-

Proceeds from public offerings of common stock, net of commissions and underwriting discounts

561,277

631,494

326,025

330,175

129,720

96,255

-

Net cash provided by financing activities

607,624

659,358

341,818

330,982

129,866

146,870

22,783

Net increase in cash, cash equivalents and restricted cash

-64,238

-113,774

138,003

-17,711

58,987

119,700

5,264

Supplemental disclosure of non-cash operating and investing activities
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

2,294

7

Conversion of preferred stock to common stock

-

-

-

-

-

92,863

-

Purchases of property and equipment included in accounts payable

65

51

138

8

-

-

-

Right-of-use assets obtained in exchange for new operating lease liabilities

872

-

-

-

-

-

-

Landlord tenant incentive included in other current assets

-

229

-

-

-

-

-

Purchases of property and equipment financed with landlord tenant incentive

-

-

1,665

-

-

-

-

Public offering costs included in accounts payable

-

-

95

-

165

-

-